T1	intervention 18 27	metformin
T2	location 138 142	U.S.
T3	eligibility 983 1059	overweight/obese premenopausal women who have elements of metabolic syndrome
T4	intervention-participants 1139 1141	75
T5	control 1146 1153	placebo
T6	control-participants 1159 1161	75
T7	duration 1167 1176	12Â months
T8	outcome-Measure 1202 1226	change in breast density
T9	outcome-Measure 1326 1357	changes in serum insulin levels
T10	outcome-Measure 1359 1461	serum insulin-like growth factor (IGF)-1 to insulin-like growth factor binding protein (IGFBP)-3 ratio
T11	outcome-Measure 1463 1480	serum IGF-2 level
T12	outcome-Measure 1483 1508	serum testosterone levels
T13	outcome-Measure 1510 1543	serum leptin to adiponectin ratio
T14	outcome-Measure 1545 1556	body weight
T15	outcome-Measure 1562 1581	waist circumference
T16	outcome-Measure 1612 1679	changes in metabolomic profiles in plasma and nipple aspirate fluid
